American Society of Hematology

ASH Meeting on Hematologic Malignancies

Early registration is now open. Hear top experts in hematologic malignancies discuss the latest developments in clinical care.

Learn more

Podcast: Navigating Future Challenges in Lymphoma

Drs. LaCasce, Weinstock, and Gotlib provide insight on the strategic lymphoma roadmap developed at the ASH Meeting on Lymphoma Biology.

Learn more

Editor Search

ASH is in the initial stage of the selection process for the next Executive Editor of Hematology: the ASH Education Program (term: 2016-2018).

Learn more

Protect Medical Research

Urge Congress to find a balanced approach to deficit reduction that does not involve further cuts to medical research.

Take action
Find a Hematologist

Find a Hematologist

Search a database of practicing hematologists in your area.

Learn more
Support Hematology

ASH Foundation

Help move hematology forward by supporting research, career development, and quality care and education programs.

Learn more
Join ASH

ASH Membership

Become part of a global network of more than 16,000 hematologists working to conquer blood diseases.

Learn more
  • Fellows and Junior Faculty Participate in 2015 ASH Clinical Research Training Institute in Latin America

    The American Society of Hematology today announced the names of ten hematologists selected to participate in the third ASH Clinical Research Training Institute in Latin America (CRTI-LA). This education and mentorship program, being held April 21-22, 2015, in Cartagena, Colombia, prior to the Society’s Highlights of ASH® meeting in Latin America, is designed to prepare current hematology and hematology/oncology fellows and junior faculty working in Latin America for careers in patient-oriented clinical research.

  • Statement from ASH President David A. Williams, MD, on Passage of Senate Bill to Repeal Sustainable Growth Rate

    Last night the Senate passed legislation permanently repealing the Sustainable Growth Rate, a flawed formula mandating annual reductions in Medicare physician payments, and replacing it with a 0.5 percent annual physician pay increase for the next five years.

  • American Society of Hematology Provides ‘Bridge Funding’ for Critical Blood Disease Research

    The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the latest recipients of the ASH Bridge Grant Awards. These one-year, $150,000 awards are designed to provide critical interim support for hematology research proposals that, despite earning high scores, could not be funded by the NIH due to severe funding reductions. The 11 ASH Bridge Grant recipients announced today join 51 hematologists that have received funding since ASH committed $9 million in Society funds to create the program in 2012.

  • Study: Gene Therapy Superior to Half-Matched Transplant for Children with “Bubble Boy Disease”

    New research published online today in Blood, the Journal of the American Society of Hematology, reports that children with “bubble boy disease” who undergo gene therapy have fewer infections and hospitalizations than those receiving stem cells from a partially matched donor. The research is the first to compare outcomes among children with the rare immune disorder – also known as X-linked severe combined immunodeficiency (SCID-X1) – receiving the two therapeutic approaches.

View all press releases
  • NIH Seeks Information on Optimizing Funding Policies and Other Strategies to Improve the Impact and Sustainability of Biomedical Research

    The NIH has released a request for information soliciting input on the possible development of new policies and strategies to improve the impact and sustainability of its funded biomedical research enterprise.  ASH members are encouraged to submit comments in response to this request.

  • CMS Issues Guidance on Biosimilar Reimbursement and Formulary Policy

    On March 30, the Centers for Medicare & Medicaid Services (CMS) issued two documents on Medicare Part B and Part D payment for biosimilars that are relevant to hematology.  On March 6, 2015, the FDA)approved filgrastim-sndz (ZARXIO Injection, Sandoz Inc.), as a biosimilar to U.S.-licensed Neupogen, which is important to hematologic therapy.  Some of the most important regimens for the treatment of patients with hematologic disorders are biologic, so the release of this information is helpful for the field.

  • IOM National Cancer Policy Forum Releases a Report on Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies

    The Institute of Medicine National Cancer Policy Forum (IOM NCPF) has released a summary report on a workshop it hosted on November 10, 2014, titled "Policy Issues in the Development and Adoption of Biomarkers for Molecularly Targeted Cancer Therapies."  This report highlights the numerous challenges raised by workshop participants on the development of biomarker tests, implementation of cancer therapies into the clinic, clinical trial structure and reimbursement issues related to molecular profiling tests.

  • New SGR Bill Released

    On March 19, the House of Representatives introduced a bill that would permanently address the SGR issue.  This bill largely follows the policy of the bill that was introduced by the committees of jurisdiction during the last Congress.  That bill, which ASH supported, eliminated the SGR update formula in favor of a new payment schedule.  Follow the link above to read more about the bill.

View all policy news
View all Hematologist articles